Publications

Detailed Information

Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme

DC Field Value Language
dc.contributor.authorChoi, In Sil-
dc.contributor.authorLee, Se Hoon-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorBang, Jae Seug-
dc.contributor.authorPaek, Sun Ha-
dc.contributor.authorKim, Suzy-
dc.contributor.authorKim, Il Han-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorKim, Dong Gyu-
dc.contributor.authorJung, Hee-Won-
dc.contributor.authorKim, Noe Kyeong-
dc.date.accessioned2009-11-13T06:08:50Z-
dc.date.available2009-11-13T06:08:50Z-
dc.date.issued2002-
dc.identifier.citationJ Neurooncol 60: 171-176en
dc.identifier.issn0167-594X (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12635665-
dc.identifier.urihttps://hdl.handle.net/10371/12137-
dc.description.abstractPURPOSE: To evaluate the efficacy and toxicity of chemotherapy with ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3-nitrosourea) plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. PATIENTS AND METHODS: Between August 1999 and July 2001, previously untreated 30 patients with histologically confirmed glioblastoma multiforme were treated. Chemotherapy consisting of up to 2 cycles of 72 h of continuous intravenous infusion of ACNU (40 mg/m2/day) and cisplatin (40 mg/m2/d) was given over a 6-week period. Radiation was begun 6 weeks after the second cycle of chemotherapy. RESULTS: Median age was 48 years (range 18-66 years) and 22 patients with residual measurable disease after surgery were eligible for response analysis. One (5%) had a complete response (CR), 36% partial response (PR), 14% stable disease (SD), and 45% progressive disease (PD) after chemotherapy. After additional radiation, 22% had CR, 22% PR, 16% SD, and 42% PD. Grades III and IV leukopenia and thrombocytopenia occurred in 18 cycles (36%) and 15 cycles (30%), respectively. No fatal complications occurred. Median time to progression was 5.9 months (95% CI 5.1-6.8 months) and median overall survival was 14.9 months (95% CI 9.1-20.7 months). CONCLUSIONS: Preradiation chemotherapy with ACNU plus cisplatin is effective and feasible in patients with gliobiastoma multiforme.en
dc.language.isoen-
dc.publisherSpringer Verlagen
dc.subjectAntineoplastic Agents/*administration & dosage/adverse effectsen
dc.subjectBrain Neoplasms/*drug therapy/mortality/radiotherapyen
dc.subjectCisplatin/*administration & dosage/adverse effectsen
dc.subjectCombined Modality Therapyen
dc.subjectGlioblastoma/*drug therapy/mortality/radiotherapyen
dc.subjectNimustine/*administration & dosage/adverse effectsen
dc.subjectSurvival Analysisen
dc.titlePhase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiformeen
dc.typeArticleen
dc.contributor.AlternativeAuthor최인실-
dc.contributor.AlternativeAuthor이세훈-
dc.contributor.AlternativeAuthor김태유-
dc.contributor.AlternativeAuthor방재석-
dc.contributor.AlternativeAuthor백선하-
dc.contributor.AlternativeAuthor김수지-
dc.contributor.AlternativeAuthor김일한-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor방영주-
dc.contributor.AlternativeAuthor김동규-
dc.contributor.AlternativeAuthor정희원-
dc.contributor.AlternativeAuthor김노경-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share